Skip to content
Baltimore News Journal – Lifestyle
Author:
Cosmos Health Inc.
Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio
June 11, 2026
Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
June 11, 2026
Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries
June 11, 2026
Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance
June 11, 2026
$20 Million in Liquid Assets Support Rapid Growth Including Acquisitions, Bio Pharma Production and Nanotechnology Initiatives for Diversified Global Heath Leader Cosmos Health, Inc. (Nasdaq: COSM)
June 10, 2026
Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
June 10, 2026
Cosmos Health Inaugurates State-of-the-Art Capsule Production Line with New 5-Year Contract Manufacturing Agreement with Provident Pharmaceuticals for 385,000 Units of CERTORUN
June 9, 2026
Cosmos Health Completes Acquisition of Strategic Intellectual Property and Expands Nanotechnology Investment Initiatives
June 8, 2026
Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories
June 5, 2026
$65.3 Million Revenue in 2025 Followed by Q1 2026 Record of $17.9 Million with Momentum Continuing in Q2 for Diversified Global Heath Leader Cosmos Health Inc. (Nasdaq: COSM)
June 4, 2026
1
2
3
4
Next Page
→